Stay updated with breaking news from David Hung. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Acquisition transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025 Acquisition adds taletrectinib, a next-generation,...
Nuvation Bio Inc. entered into an Agreement and Plan of Merger to acquire AnHeart Therapeutics Ltd. on March 24, 2024. Nuvation Bio entered into a definitive agreement for Nuvation Bio to acquire...
Determined maximum tolerated dose in Phase 1 monotherapy study of NUV-868; Phase 1b studies of NUV-868 in combination with olaparib or enzalutamide remain ongoing Received U.S. Food and Drug...
MARKHAM, Ontario, Jan. 17, 2024 -- Sienna Senior Living Inc. announced that it will report its 2023 fourth quarter results after market close on Tuesday, February 20, 2024. Nitin Jain, President...
Nuvation Bio Inc. , a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of...